RESUMO
BACKGROUND: Platelet storage lesions are structural and biochemical changes in platelet concentrates (PCs), and depend on variables in collection and processing, as well as secondary procedures and storage conditions; such lesions can be mitigated by the use of platelet additive solutions (PASs). STUDY DESIGN AND METHODS: This study investigated release of the inflammatory markers sCD40L and sCD62P by single-donor apheresis platelet concentrates (SDA-PCs) and buffy coat-derived pooled platelet concentrates (PPCs) before and after storage. SDA-PC and PPC samples (n = 9089) processed by various methods and stored for different durations were obtained following production in one regional setting, the French National Blood Service. Soluble factors were quantified in PC supernatants immediately after processing and at the time of delivery, using biological testing technology (Luminex). RESULTS: SDA-PCs appeared more activated than PPCs at the end of the production step (i.e., prior to storage); however, proinflammatory soluble factors exhibited greater increases in PPCs than in SDA-PCs during storage. In SDA-PCs, PAS-D (65%) led to reduced secretion of sCD62P, but favored secretion of sCD40L, compared with the alternative PAS-E. CONCLUSION: These data stress the importance of the production (processing) steps of PC manufacture and of storage. The extent to which they affect patient outcomes awaits further investigation in clinical studies.
Assuntos
Buffy Coat/metabolismo , Ligante de CD40/metabolismo , Selectina-P/metabolismo , Plaquetoferese/métodos , Buffy Coat/citologia , Preservação de Sangue , Humanos , Inflamação/metabolismoRESUMO
BACKGROUND: Leukoreduction of labile blood components dramatically decreases the frequency of minor, intermediate, and severe adverse events (AEs), referred to as acute transfusion reactions (ATRs), especially after transfusion of platelet components (PCs). The pathophysiology of AEs may result from accumulation of soluble, secreted, platelet (PLT) factors with proinflammatory functions stored in PCs. Thus, several cosynergizing factors associated with PLT accumulation in PCs may contribute to clinically reported ATRs with inflammatory symptoms. STUDY DESIGN AND METHODS: We screened for 65 PLT-associated secretory products in PCs that caused ATRs and identified PLT molecules associated with ATRs and inflammation. A functional in vitro study using PC supernatants assayed on reporting immune cells was performed to indicate relevance. RESULTS: Among 10,600 apheresis PCs, 30 caused inflammatory ATRs and contained significantly elevated levels of soluble CD40 ligand (sCD40L), interleukin (IL)-27, and soluble OX40 ligand (sOX40L). Normal PLTs secreted IL-27 and sOX40L at bioactive concentrations upon thrombin stimulation and were up regulated in association with ATRs, similar to sCD40L. Other secreted products were identified but not investigated further as their positivity was not consistent. CONCLUSIONS: This study demonstrates the putative participation of PLT-derived sOX40L, IL-27, and sCD40L, which accumulate in PC supernatants, with inflammatory-type ATRs. Further studies are required to determine the clinical significance of these findings to forecast preventive measures whenever possible.
Assuntos
Plaquetas/metabolismo , Ligante de CD40/metabolismo , Interleucina-27/metabolismo , Ligante OX40/metabolismo , Transfusão de Plaquetas/efeitos adversos , Plaquetas/imunologia , Ensaio de Imunoadsorção Enzimática , Humanos , Fatores Imunológicos/metabolismoRESUMO
BACKGROUND: COVID-19 convalescent plasma (CCP) contains neutralising anti-SARS-CoV-2 antibodies that may be useful as COVID-19 passive immunotherapy in patients at risk of developing severe disease. Such plasma from convalescent patients may also have additional immune-modulatory properties when transfused to COVID-19 patients. METHODS: CCP (n = 766) was compared to non-convalescent control plasma (n = 166) for soluble inflammatory markers, ex-vivo inflammatory bioactivity on endothelial cells, neutralising auto-Abs to type I IFNs and reported adverse events in the recipients. FINDINGS: CCP exhibited a statistically significant increase in IL-6 and TNF-alpha levels (0.531 ± 0.04 vs 0.271 ± 0.04; (95% confidence interval [CI], 0.07371-0.4446; p = 0.0061) and 0.900 ± 0.07 vs 0.283 ± 0.07 pg/mL; (95% [CI], 0.3097-0.9202; p = 0.0000829) and lower IL-10 (0.731 ± 0.07 vs 1.22 ± 0.19 pg/mL; (95% [CI], -0.8180 to -0.1633; p = 0.0034) levels than control plasma. Neutralising auto-Abs against type I IFNs were detected in 14/766 (1.8%) CCPs and were not associated with reported adverse events when transfused. Inflammatory markers and bioactivity in CCP with or without auto-Abs, or in CCP whether or not linked to adverse events in transfused patients, did not differ to a statistically significant extent. INTERPRETATION: Overall, CCP exhibited moderately increased inflammatory markers compared to the control plasma with no discernible differences in ex-vivo bioactivity. Auto-Abs to type I IFNs detected in a small fraction of CCP were not associated with reported adverse events or differences in inflammatory markers. Additional studies, including careful clinical evaluation of patients treated with CCP, are required in order to further define the clinical relevance of these findings. FUNDING: French National Blood Service-EFS, the Association "Les Amis de Rémi" Savigneux, France, the "Fondation pour la Recherche Médicale (Medical Research Foundation)-REACTing 2020".
Assuntos
COVID-19 , Humanos , Estudos de Coortes , Células Endoteliais , Soroterapia para COVID-19 , Imunização Passiva , Anticorpos AntiviraisRESUMO
Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if administered early in the disease, particularly in patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms. This study examined the influence of photochemical Pathogen Reduction Treatment (PRT) using amotosalen-HCl and UVA light in comparison with untreated control convalescent plasma (n= 72 - paired samples) - cFFP, regarding soluble inflammatory factors: sCD40L, IFN-alpha, IFN-beta, IFN-gamma, IL-1 beta, IL-6, IL-8, IL-10, IL-18, TNF-alpha and ex-vivo inflammatory bioactivity on endothelial cells. We didn't observe significant modulation of the majority of inflammatory soluble factors (8 of 10 molecules tested) pre- or post-PRT. We noted that IL-8 concentrations were significantly decreased in cFFP with PRT, whereas the IL-18 concentration was increased by PRT. In contrast, endothelial cell release of IL-6 was similar whether cFFP was pre-treated with or without PRT. Expression of CD54 and CD31 in the presence of cFFP were similar to control levels, and both were significant decreased in when cFFP had been pre-treated by PRT. It will be interesting to continue investigations of IL-18 and IL-8, and the physiopathological effect of PRT- treated convalescent plasma and in clinical trials. But overall, it appears that cFFP post-PRT were not excessively pro-inflammatory. Further research, including a careful clinical evaluation of CCP-treated patients, will be required to thoroughly define the clinical relevance of these findings.
Assuntos
COVID-19 , Pandemias , Humanos , COVID-19/terapia , Células Endoteliais , Interleucina-10 , Interleucina-18 , Interleucina-1beta , Interleucina-6 , Interleucina-8 , Tecnologia , Fator de Necrose Tumoral alfa , Raios Ultravioleta , Soroterapia para COVID-19RESUMO
BACKGROUND: Recent studies have demonstrated that infused platelets (PLTs) can promote inflammation. The objective of this study was to evaluate the impact of storage of transfusion-grade PLTs on the peripheral blood mononuclear cells (PBMNCs) of the recipient. STUDY DESIGN AND METHODS: An in vitro cell model system was established to measure the degree of activation of donor PLTs during 5 days of their storage and then to measure immune cell activation by detecting marker expression in coculture experiments. RESULTS: The level of soluble CD62p increased significantly by Day 3, and membrane expression of CD62p increased significantly from Day 2, indicating some degree of PLT activation over time during storage (p < 0.05). Donor PLTs and PBMNC subsets (monocytes, B cells, and T cells) from recipients were cocultured for 48 hours. The number of PLT-PBMNC subset doublets detected by flow cytometry was correlated with the PLT storage time after Day 3 (p < 0.05), indicating consistent binding of PLTs to PBMNCs. The results of these experiments showed that there was a consistent and significant increase in expression of conventional activation markers of T cells, B cells, and monocytes compared with appropriate controls (p < 0.05 to <0.01). CONCLUSION: The results of this study indicate that, from Day 3 onward, activation markers are consistently expressed on PLTs. From these results, we conclude that activated PLTs may affect PBMNC interactions in recipients.
Assuntos
Plaquetas/metabolismo , Leucócitos Mononucleares/metabolismo , Modelos Biológicos , Selectina-P/biossíntese , Ativação Plaquetária , Transfusão de Plaquetas , Preservação Biológica , Plaquetas/citologia , Técnicas de Cocultura , Regulação da Expressão Gênica , Humanos , Inflamação/etiologia , Inflamação/metabolismo , Leucócitos Mononucleares/citologia , Fatores de TempoRESUMO
B-cell expression of certain Toll-like receptors (TLRs) is important in linking innate and adaptive immune responses in normal and pathological conditions. The expression of TLR9 plays a role in the recognition of conserved pathogen motifs in a manner that is dependent on B-cell localization, deduced from B-cell phenotype. The nature of TLR9 function is unclear. A first step in unravelling the function of this pattern recognition receptor is to discover the precise nature of the cell types that express TLR9. This study used three-colour flow cytometry to characterize the B lymphocytes from human peripheral blood mononuclear cells (PBMCs) that express TLR9 on the surface. We sorted TLR9-positive B and non-B cells from the PBMC population and detected TLR9 expression on naïve and memory B cells. Moreover, we identified two discrete subpopulations of B cells: CD19(+) CD27(-) CD23(+) cells and CD19(+) CD27(high) CD80(+) cells. These subpopulations expressed high levels of membrane TLR9 and exhibited a strong in vitro response to binding a relevant CpG motif by secreting high levels of interleukin-6 (compared to controls). Our finding that this pattern recognition receptor is expressed on a variety of cell subsets adds to the current understanding of the functional complexity of B-cell membrane TLR9.
Assuntos
Subpopulações de Linfócitos B/imunologia , Interleucina-6/biossíntese , Receptor Toll-Like 9/sangue , Antígeno B7-1/sangue , Membrana Celular/imunologia , Células Cultivadas , Ilhas de CpG/imunologia , Humanos , Memória Imunológica/imunologia , Ativação Linfocitária/imunologia , Receptores de IgE/sangue , Membro 7 da Superfamília de Receptores de Fatores de Necrose Tumoral/sangueRESUMO
BACKGROUND: Dendritic cells (DCs) are antigen presenting cells capable of inducing innate and adaptive immune responses. According to the stimulus and their maturation state, DCs induce immunogenic or tolerogenic responses. Platelets (PLTs), which are involved in haemostasis and inflammation, can also interact with DCs. In this study, we examined the effect of PLTs on DC maturation in vitro. Human monocyte-derived DCs were co-cultured for 2 days with homologous PLTs either in the same well or in 0.4 mum-pore size filter-separated compartments. RESULTS: Confocal microscopy showed the attachment of PLTs to DC membranes. The DC receptor involved in this interactions was found to be CD162. In addition, we observed that DCs co-cultured with PLTs in filter-separated compartments acquired a mature phenotype (high CD80, CD86, and intermediate CD83 expression; IL-12(p70) production; efficient stimulation of autologous CD4+ T cell proliferation), while DCs co-cultured with PLTs in the same compartment did not undergo phenotypic maturation, did not secrete IL-12(p70) or IL-1beta, but instead induced moderate Th2-polarized T cell proliferation. CONCLUSION: These data indicate that (i) PLTs secrete a soluble DC-activating factor that was demonstrated not to be soluble CD40-Ligand (CD154; as could have been expected from in vivo and previous in vitro work) but to be nucleotide, and (ii) that cell-to-cell contact did not induce DC maturation, possibly because nucleotide release by PLTs was prevented by direct contact with DCs. This work demonstrates that PLTs are active elements of the immune system that might play a role in balancing the ability of DCs to polarize T cell responses, therefore making them critical factors in transfusion processes.
Assuntos
Plaquetas/metabolismo , Células Dendríticas/imunologia , Células Dendríticas/metabolismo , Antígenos CD/imunologia , Antígenos CD/metabolismo , Antígeno B7-1/imunologia , Antígeno B7-1/metabolismo , Antígeno B7-2/imunologia , Antígeno B7-2/metabolismo , Plaquetas/citologia , Linfócitos T CD4-Positivos/imunologia , Diferenciação Celular , Técnicas de Cocultura , Citocinas/imunologia , Citocinas/metabolismo , Células Dendríticas/citologia , Humanos , Imunoglobulinas/imunologia , Imunoglobulinas/metabolismo , Ativação Linfocitária , Glicoproteínas de Membrana/imunologia , Glicoproteínas de Membrana/metabolismo , Antígeno CD83RESUMO
OBJECTIVE: Blood platelets represent a link between hemostasis, inflammation, and tissue repair. Their role in immune responses and inflammation mainly involves many molecules, among which Toll-like receptor, major histocompatibility complex class I, CD40 and CD154/CD40 ligand (CD40L). As platelets are the major purveyor of soluble CD40L (sCD40L), we sought to determine their involvement in CD40/CD40L-dependent immune responses and to understand the interactions between platelets and peripheral B lymphocytes. MATERIALS AND METHODS: We examined the capacity of platelets to bind nonstimulated B cells, and phenotypic changes by flow cytometry and confocal scanning laser microscopy. Modulation of cytokines/chemokines and total levels of immunoglobulin (Ig) A, IgG, IgM, and IgG subclasses in supernatants of coculture, platelets, and B lymphocytes was performed by sandwich enzyme-linked immunosorbent assay and differential production of cytokine mRNA as determined by reverse transcriptase polymerase chain reaction. RESULTS: In coculture, platelets and B lymphocytes were mutually activated, as demonstrated by the increased expression of platelet CD62p and B-cell CD86. Platelet/B-cell interactions were accompanied by changes in membrane expression of CD40 and CD40L by both platelets and B lymphocytes. IL12p70 and IL8 gene transcription were significantly reduced, which was attributable to B cells. Conversely, there was a significant, platelet-dependent reduction of sCD40L and RANTES mRNA expression. After a 3-day incubation with platelets, differentiated B cells increased their in vitro production of IgG1, IgG2, and IgG3, but not IgG4, IgA, or IgM. CONCLUSION: These data emphasize the potentially important role of platelets in the adaptive immune response. Platelets have an immunoregulatory role that might be applied clinically in multitransfused patients (e.g., hematopoietic stem cell transplantation).
Assuntos
Linfócitos B/imunologia , Plaquetas/fisiologia , Imunoglobulinas/metabolismo , Ativação Linfocitária , Células Cultivadas , Técnicas de Cocultura , Citometria de Fluxo , Humanos , Imunidade Celular/imunologia , Leucócitos Mononucleares/imunologiaRESUMO
Platelet transfusions may be associated with certain adverse effects in recipients, potentially caused by the presence of biological response modifiers contained in the platelet concentrates. The aim of this study is to identify the parameters that reflect platelet activation during both the preparation process and the storage of platelet concentrates. A total of 3,949apheresis platelet concentrate samples were studied with regard to parameters related to the donor as well as to the preparation process and their storage. Key glycoproteins characteristic of platelet activation, i.e. soluble CD40L and CD62P, were quantified in platelet concentrate supernatants on completion of their processing and during storage, using Luminex technology. We observed an increase in soluble factors over time. However, the different parameters studied in connection either with the donors or with the donations, such as (i) donor gender, (ii) donor blood group, (iii) time of collection and (iv) type of apheresis separator, do not seem to have any effect on platelet activation or the release of soluble CD40L and CD62P.
Assuntos
Plaquetas , Preservação de Sangue , Ligante de CD40/análise , Selectina-P/análise , Ativação Plaquetária , Transfusão de Plaquetas , Plaquetoferese , Doadores de Sangue , Plaquetas/metabolismo , Ligante de CD40/biossíntese , Feminino , Humanos , Masculino , Selectina-P/biossíntese , Fatores de TempoRESUMO
BACKGROUND: Cytokines have essential roles on intercellular communications and are effective in using a variety of intracellular pathways. Among this multitude of signalling pathways, the NF-kappaB (nuclear factor kappaB) and STAT (signal transducer and activator of transcription) families are among the most frequently investigated because of their importance. Indeed, they have important role in innate and adaptive immunity. Current techniques to study NF-kappaB and STAT rely on specific ELISAs, Western Blots and--most recently described--flow cytometry; so far, investigation of such signalling pathways are most commonly performed on homogeneous cells after purification. RESULTS: The present investigation aimed at developing a flow cytometry technique to study transcription factors in various cellular types such as mixtures of B-cells, T-lymphocytes and monocytes/macrophages stimulated in steady state conditions (in other words, as peripheral blood mononuclear cells). To achieve this goal, a two step procedure was carried out; the first one consisted of stimulating PBMCs with IL1beta, sCD40L and/or IL10 in such a manner that optimal stimulus was found for each cell subset (and subsequent signal transduction, therefore screened by specific ELISA); the second step consisted of assessing confirmation and fine delineation of technical conditions by specific Western-Blotting for either NF-kappaB or STAT products. We then went on to sensitize the detection technique for mixed cells using 4 color flow cytometry. CONCLUSION: In response to IL1beta, or IL10, the levels of phosphorylated NF-kappaB and STAT3--respectively--increased significantly for all the studied cell types. In contrast, B-cells and monocytes/macrophages--but, interestingly, not T-lymphocytes (in the context of PBMCs)--responded significantly to sCD40L by increasing phosphorylated NF-kappaB.
Assuntos
Citometria de Fluxo/métodos , Leucócitos Mononucleares/metabolismo , NF-kappa B/metabolismo , Fator de Transcrição STAT3/metabolismo , Transdução de Sinais/fisiologia , Linfócitos B/citologia , Linfócitos B/imunologia , Ligante de CD40/imunologia , Células Cultivadas , Humanos , Interleucina-10/imunologia , Interleucina-1beta/imunologia , Leucócitos Mononucleares/citologia , Ativação Linfocitária , Macrófagos/citologia , Macrófagos/imunologia , Fator de Transcrição STAT3/genética , Linfócitos T/citologia , Linfócitos T/imunologiaRESUMO
Platelet concentrates account for near 10% of all labile blood components but are responsible for more than 25% of the reported adverse events. Besides factors related to patients themselves, who may be particularly at risk of side effects because of their underlying illness, there are aspects of platelet collection and storage that predispose to adverse events. Platelets for transfusion are strongly activated by collection through disposal equipment, which can stress the cells, and by preservation at 22 °C with rotation or rocking, which likewise leads to platelet activation, perhaps more so than storage at 4 °C. Lastly, platelets constitutively possess a very large number of bioactive components that may elicit pro-inflammatory reactions when infused into a patient. This review aims to describe approaches that may be crucial to minimising side effects while optimising safety and quality. We suggest that platelet transfusion is complex, in part because of the complexity of the "material" itself: platelets are highly versatile cells and the transfusion process adds a myriad of variables that present many challenges for preserving basal platelet function and preventing dysfunctional activation of the platelets. The review also presents information showing--after years of exhaustive haemovigilance--that whole blood buffy coat pooled platelet components are extremely safe compared to the gold standard (i.e. apheresis platelet components), both in terms of acquired infections and of immunological/inflammatory hazards.
Assuntos
Preservação de Sangue/métodos , Segurança do Sangue/métodos , Transfusão de Plaquetas/métodos , HumanosRESUMO
Although convalescent plasma (CP) transfusion was prioritized among potential Ebola treatments by the World Health Organization, there were concerns on the feasibility of its implementation. We report on the successful organization of donor mobilization and plasma collection as part of the Ebola-Tx clinical trial from November 2014 to July 2015 in Conakry, Guinea. Project implementation registers, tools and reports, mission reports, and minutes of research team meetings were used to reconstruct the sequence of events on how donor mobilization was organized, plasmapheresis was set up, and how effective this approach was in collecting CP. An initial needs assessment of the Guinean National Blood Transfusion Center resulted in targeted training of staff on site, resulting in autonomy and independent production of CP within 3 months. The Conakry Ebola Survivors Association played a direct role in donor mobilization and organization of CP donations. A total of 98 Ebola survivors were screened for plasma donation, of which 84 were found eligible for plasmapheresis. Of these, 26 (30.9%) were excluded. The remaining 58 donors made a total of 90 donations, corresponding to 50.9 L of CP. This sufficed to treat the 99 eligible patients enrolled in the trial. Within a poor resource emergency context, transfusion capacity could be rapidly improved through the strengthening of local capacities and gradual transfer of skills coupled with active involvement of Ebola survivors. However, large-scale plasma collection or multisite studies may require further adaptations of both strategy and logistics. The Ebola-Tx trial was funded by the European Union and others.
Assuntos
Doadores de Sangue , Transfusão de Sangue/métodos , Doença pelo Vírus Ebola/terapia , Ensaios Clínicos como Assunto/organização & administração , Feminino , Guiné , Doença pelo Vírus Ebola/sangue , Humanos , Masculino , Plasmaferese/métodos , SobreviventesRESUMO
The level of safety attained in blood transfusion now makes this a discipline better managed care activities. This was achieved both by scientific advances and policy decisions regulating and supervising the activity, as well as by the quality system, which we recall that affects the entire organizational structure, responsibilities, procedures, processes and resources in place to achieve quality management. So, an effective quality system provides a framework within which activities are established, performed in a quality-focused way and continuously monitored to improve outcomes. This system quality has to irrigate all the actors of the transfusion, just as much the establishments of blood transfusion than the health establishments.
Assuntos
Bancos de Sangue/organização & administração , Segurança do Sangue , Coleta de Amostras Sanguíneas , Gestão da Segurança/métodos , Gestão da Segurança/organização & administração , Reação Transfusional , Doadores de Sangue/provisão & distribuição , Segurança do Sangue/métodos , Segurança do Sangue/normas , Coleta de Amostras Sanguíneas/efeitos adversos , Coleta de Amostras Sanguíneas/métodos , Coleta de Amostras Sanguíneas/normas , Transfusão de Sangue/métodos , Transfusão de Sangue/normas , Seleção do Doador/métodos , Seleção do Doador/organização & administração , Humanos , Garantia da Qualidade dos Cuidados de SaúdeRESUMO
BACKGROUND: Platelet component (PC) transfusion leads occasionally to inflammatory hazards. Certain BRMs that are secreted by the platelets themselves during storage may have some responsibility. METHODOLOGY/PRINCIPAL FINDINGS: First, we identified non-stochastic arrangements of platelet-secreted BRMs in platelet components that led to acute transfusion reactions (ATRs). These data provide formal clinical evidence that platelets generate secretion profiles under both sterile activation and pathological conditions. We next aimed to predict the risk of hazardous outcomes by establishing statistical models based on the associations of BRMs within the incriminated platelet components and using decision trees. We investigated a large (n = 65) series of ATRs after platelet component transfusions reported through a very homogenous system at one university hospital. Herein, we used a combination of clinical observations, ex vivo and in vitro investigations, and mathematical modeling systems. We calculated the statistical association of a large variety (n = 17) of cytokines, chemokines, and physiologically likely factors with acute inflammatory potential in patients presenting with severe hazards. We then generated an accident prediction model that proved to be dependent on the level (amount) of a given cytokine-like platelet product within the indicated component, e.g., soluble CD40-ligand (>289.5 pg/109 platelets), or the presence of another secreted factor (IL-13, >0). We further modeled the risk of the patient presenting either a febrile non-hemolytic transfusion reaction or an atypical allergic transfusion reaction, depending on the amount of the chemokine MIP-1α (<20.4 or >20.4 pg/109 platelets, respectively). CONCLUSIONS/SIGNIFICANCE: This allows the modeling of a policy of risk prevention for severe inflammatory outcomes in PC transfusion.
Assuntos
Plaquetas/imunologia , Modelos Estatísticos , Transfusão de Plaquetas/efeitos adversos , Adulto , Idoso , Ligante de CD40/sangue , Quimiocina CCL3/sangue , Simulação por Computador , Citocinas/metabolismo , Árvores de Decisões , Feminino , Humanos , Inflamação , Interleucina-13/sangue , Masculino , Pessoa de Meia-Idade , Risco , Adulto JovemRESUMO
BACKGROUND: Platelets participate in tissue repair and innate immune responses. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are well-characterized I-type lectins, which control apoptosis. METHODOLOGY/PRINCIPAL FINDINGS: We characterized the expression of Siglec-7 in human platelets isolated from healthy volunteers using flow cytometry and confocal microscopy. Siglec-7 is primarily expressed on α granular membranes and colocalized with CD62P. Siglec-7 expression was increased upon platelet activation and correlated closely with CD62P expression. Cross-linking Siglec-7 with its ligand, ganglioside, resulted in platelet apoptosis without any significant effects on activation, aggregation, cell morphology by electron microscopy analysis or secretion. We show that ganglioside triggered four key pathways leading to apoptosis in human platelets: (i) mitochondrial inner transmembrane potential (ΔΨm) depolarization; (ii) elevated expression of pro-apoptotic Bax and Bak proteins with reduced expression of anti-apoptotic Bcl-2 protein; (iii) phosphatidylserine exposure and (iv), microparticle formation. Inhibition of NAPDH oxidase, PI3K, or PKC rescued platelets from apoptosis induced by Siglec-7 recruitment, suggesting that the platelet receptors P2Y1 and GPIIbIIIa are essential for ganglioside-induced platelet apoptosis. CONCLUSIONS/SIGNIFICANCE: The present work characterizes the role of Siglec-7 and platelet receptors in regulating apoptosis and death. Because some platelet pathology involves apoptosis (idiopathic thrombocytopenic purpura and possibly storage lesions), Siglec-7 might be a molecular target for therapeutic intervention/prevention.
Assuntos
Antígenos de Diferenciação Mielomonocítica/metabolismo , Plaquetas/citologia , Plaquetas/metabolismo , Lectinas/metabolismo , Antígenos de Diferenciação Mielomonocítica/genética , Apoptose/genética , Apoptose/fisiologia , Plaquetas/ultraestrutura , Células Cultivadas , Humanos , Lectinas/genética , Potencial da Membrana Mitocondrial , Microscopia ConfocalAssuntos
Ligante de CD40/sangue , Lipopolissacarídeos/farmacologia , Receptor 2 Toll-Like/efeitos dos fármacos , Receptor 4 Toll-Like/efeitos dos fármacos , Receptor Toll-Like 9/efeitos dos fármacos , Humanos , Receptor 2 Toll-Like/fisiologia , Receptor 4 Toll-Like/fisiologia , Receptor Toll-Like 9/fisiologiaRESUMO
BACKGROUND: Blood platelets (PLTs) are critical for hemostasis, and they contain biologically active constituents with the potential to modulate inflammatory responses. This study examined the effects of photochemical pathogen inactivation treatment (PCT) on the release of cytokines and/or chemokines from PLT components. STUDY DESIGN AND METHODS: Double-dose apheresis PLT components were suspended in plasma-PLT additive solution mixtures and divided into paired therapeutic units. One unit served as an untreated control and the other unit was treated with PCT. PLT concentrations, pH, and levels of cytokines and/or chemokines (CD62p, platelet-derived growth factor-AB, interleukin [IL]-8, soluble CD40 ligand [sCD40L], IL-1beta, and tumor necrosis factor alpha) were measured during 7 days of storage in PLT component supernatants and PLT lysates. RESULTS: PLT content, pH, and cytokine and/or chemokine content and release from PLT component prepared with PCT were not different (p > 0.05) from paired control components during storage. Levels of sCD40L, however, increased significantly during storage while decreasing in parallel within PLT lysates, although no differences were detected between paired PCT and control PLT component. CONCLUSION: PCT did not increase the release or secretion of PLT chemokines and/or cytokines over a 7-day period compared to conventional PLT component.
Assuntos
Plaquetas/imunologia , Plaquetas/metabolismo , Preservação de Sangue/métodos , Fatores Imunológicos/metabolismo , Fotoquímica , Biomarcadores/metabolismo , Patógenos Transmitidos pelo Sangue , Quimiocinas/metabolismo , Citocinas/metabolismo , Humanos , Transfusão de PlaquetasRESUMO
BACKGROUND: Blood platelets (PLTs) link the processes of hemostasis and inflammation. Recent studies have demonstrated that PLTs promote immunity and inflammation mainly by means of the CD40/CD40L pathway. Our objective was to describe the accumulation of cytokines in PLT concentrates during storage. STUDY DESIGN AND METHODS: Pools of PLT concentrates were prepared, separated from plasma, and resuspended in clinical-grade storage medium; samples were taken on Days 0, 1, 2, 3, and 5 for analysis, without replacement (i.e., without soluble protein dilution). Interleukin (IL)-6, IL-8, PLT-derived growth factor (PDGF)-AA, soluble CD40 ligand (sCD40L), RANTES, and transforming growth factor-beta production were measured by specific enzyme-linked immunosorbent assays. RESULTS: Over time, the levels of RANTES, IL-8, and IL-6 were stable. In contrast, the levels of PDGF-AA and sCD40L increased. Ex vivo production of sCD40L was quantified at levels sufficient to induce B-cell effects based on previous studies of in vitro induced B-cell activation and differentiation by sCD40L. Cytokine and/or chemokine levels were generally higher in PLT concentrate supernatants and/or PLT lysates in comparison to PLT-free plasma, allowing the determination of which cytokine and/or chemokine was absorbed or secreted by transfusion-grade PLTs over time. CONCLUSION: Our data provide evidence that stored PLTs contain molecules with known immunomodulatory competence and secrete them differentially over time during storage for transfusion purposes.
Assuntos
Plaquetas/imunologia , Preservação de Sangue , Fatores Imunológicos/metabolismo , Plaquetas/metabolismo , Ligante de CD40/análise , Quimiocina CCL5/análise , Citaferese , Citocinas/análise , Humanos , Interleucinas/análise , Transfusão de Plaquetas/métodos , Transfusão de Plaquetas/normas , Fator de Crescimento Derivado de Plaquetas/análise , Fatores de TempoRESUMO
Platelets are primarily involved in thrombosis and haemostasis, and they have recently been shown to have a role in innate immunity and in inflammation. We have determined the markers of innate immunity that are expressed by platelets, specifically the Toll-like receptors (TLR), originating from mixes of platelet concentrates (MPC, n = 5) between day zero and day five after blood collection. The surface membrane and intracellular expression of TLR were measured, both after and without permeabilization, using flow cytometry. We observed weak expression of TLR2, TLR4 and TLR9 on the surface of CD41(+) platelets. The expression levels of TLR4 were high (59 +/- 2.2%). Moreover, there was a significant expression of TLR2 (47.5 +/- 4.8%), TLR4 (78.8 +/- 1.3%) and TLR9 (34.2 +/- 7.5%) in the cytoplasm of CD41(+) platelets. The expression of the three receptors did not change significantly during the course of the 5 day observation period. The percentage of TLR expression is significantly modulated between activated versus non-activated platelets, both after and without permeabilization (P < 0.01). Study of the expression of TLR could increase our knowledge of the level of platelet participation during an immune reaction and inflammation. In the same way as the platelet ligand/receptor pair CD40L/CD40 is, the TLR are expressed by platelets, and could serve as a link between innate and adaptive immunity.